Concepedia

Publication | Open Access

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With <i>BRAF</i> -Mutant Advanced Melanoma

DOIFull Paper Access

34

Citations

37

References

2018

Year

Ahmad A. Tarhini, David F. McDermott, Apoorva Ambavane, Komal Gupte-Singh, Valerie Aponte Ribero, Corey Ritchings, Ágnes Benedict, Sumati Rao, Meredith M. Regan, Michael B. Atkins
Immunotherapy

Abstract

Initiating treatment with anti-PD-1 + anti-CTLA-4 was more cost-effective than initiation with anti-PD-1 monotherapy or BRAF+MEK inhibitors.

References

YearCitations

Page 1